Clinical Trials Browser

Phase 1 × INDUSTRY × nintedanib × Clear all

NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Phase 1 Completed

19 enrolled 21 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01346540 2025-02-12

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Phase 1 Completed

16 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02300298 2025-02-11

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Phase 1 Completed

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02182219 2025-01-22

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT02668393 2021-01-29

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Phase 1 Completed

14 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02751385 2019-03-14

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Phase 1 Terminated

2 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Phase 1 Completed

30 enrolled 24 charts

Neoplasms

NCT01594125 2016-02-12

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Phase 1 Completed

30 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Phase 1 Completed

41 enrolled 24 charts

Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Phase 1 Terminated

2 enrolled 5 charts

Ovarian Neoplasms

NCT02182102 2014-07-18

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Phase 1 Completed

Neoplasms

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Phase 1 Completed

Other solid neoplasm

Malignant Solid Tumour

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Phase 1 Completed

Neoplasms